Two independent research teams have used cell culture methods to show that excessive HGF/SF activity drives resistance to BRAF inhibitors in melanoma. The findings could provide a rationale for combining HGF/SF or MET inhibitors with BRAF inhibitors to overcome treatment resistance in the disease.